Cite
PB1897: DISCONTINUATION OF IMATINIB IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE
MLA
Y. Bouchakor Moussa, et al. “Pb1897: Discontinuation of Imatinib in Patients Followed for Chronic Myeloid Leukemia in Deep Molecular Response.” HemaSphere, vol. 6, June 2022, pp. 1776–77. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4783838eb09148f2fb217bb4c17ea50c&authtype=sso&custid=ns315887.
APA
Y. Bouchakor Moussa, S. Taoussi, S. Oukid, F. Lamraoui, N. Rekab, K. M. Benlabiod, H. Brahimi, M. T. Abad, & M. Bradai. (2022). Pb1897: Discontinuation of Imatinib in Patients Followed for Chronic Myeloid Leukemia in Deep Molecular Response. HemaSphere, 6, 1776–1777.
Chicago
Y. Bouchakor Moussa, S. Taoussi, S. Oukid, F. Lamraoui, N. Rekab, K. M. Benlabiod, H. Brahimi, M. T. Abad, and M. Bradai. 2022. “Pb1897: Discontinuation of Imatinib in Patients Followed for Chronic Myeloid Leukemia in Deep Molecular Response.” HemaSphere 6 (June): 1776–77. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4783838eb09148f2fb217bb4c17ea50c&authtype=sso&custid=ns315887.